Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Content Oklo: The Bottom Is In, and the Upside Potential Is NuclearReported by Thomas Hughes. Article Posted: 3/19/2026. 
Key Points - Oklo's FY2025 update revealed progress, and the market liked it; the diversification strategy is progressing.
- Analysts responded favorably, affirming the forecast for a 50% stock price increase.
- Short-covering and institutional accumulation align with a technical bottom, setting this market up to sustain a rebound in 2026.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
Oklo Inc. (NYSE: OKLO) faces headwinds, including a lack of revenue and profits, but investors appear focused on its long-term potential. The company's fiscal year 2025 (FY2025) progress report and updates indicate it is on track with key milestones. The market response — and the wave of analyst updates that followed — suggests that long-term opportunity is outweighing near-term financials. Analysts Focus on Oklo's Long-Term Opportunity MarketBeat tracked about half a dozen rating and target revisions within the first 12 hours after the release. There was one price-target cut, but it was offset by a larger number of affirmed ratings and target increases, with no downgrades. BlackRock, JPMorgan, Goldman Sachs, and Fidelity are accumulating shares of one scarce resource - the fuel powering a new $382 trillion digital financial infrastructure. With $909 billion migrating onto these new digital rails every single day, demand is projected to climb 12,000% by April 2027. The Nasdaq has SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this shift. Veteran tech investor Andy Howard has identified the single asset positioned to power the entire grid - and the free ticker is available now. See the scarce asset behind the $382 trillion money grid today The activity aligns with the broader trend: growing coverage, a steady Moderate Buy consensus, a 58% Buy-side bias, and an upward drift in price targets. Those price targets matter — consensus levels imply more than 50% upside versus mid-March lows. Analysts expressed concern about the 2025 results, but they remain primarily focused on the long-term opportunity and progress on Nuclear Regulatory Commission licensing. The company secured its first license through its subsidiary Atomic Alchemy, which produces isotopes. The license permits the receipt, possession, storage, processing, repackaging and distribution of up to two curies of radium-226 — roughly two grams. Two grams isn't much, and radium-226 has limited standalone value. It was once used in medical applications but is now challenging to handle and remediate. However, radium-226 is a feedstock for producing actinium, which is among the most expensive elements and is used in specialized cancer treatments that can cost roughly $20,000 per dose. The implication for investors is that Oklo's diversification strategy has been validated and a revenue stream has been opened. Revenue may take a few quarters to materialize, but it could arrive well before the commercialization of its core nuclear reactor technologies. Institutional and Short-Selling Data Reveal the Bottom is In for Oklo Stock Institutional and short-selling data point to a market bottom for Oklo. Short interest remains elevated, near 15% as of early March, but it has fallen from its peak around Oklo's October 2025 highs and is likely to keep declining in upcoming reports. Institutional ownership, by contrast, has increased sharply since the Q2 2025 plunge and hit record levels in early 2026. Institutions now own roughly 85% of the outstanding shares, providing strong support, and are accumulating at about $3 of purchases for every $1 of sales. If these trends persist, the available float should shrink significantly in the coming months, putting upward pressure on the share price. A catalyzing news event could even trigger a short squeeze. Dilutive Headwinds Cease in 2026 Shareholder dilution was a headwind in 2025 but appears to be moderating in 2026. The share count is up about 50% year over year, and the balance sheet is well capitalized. FY2026 plans suggest the company has sufficient capital to fund projects at the current burn rate for roughly two years, which should give time for secondary revenue streams — like the isotope business — to develop. The offset: profitability isn't expected until 2030, so additional capital raises may be required down the road. The technical setup is encouraging. OKLO's stock is well below its highs and looked oversold in March. The MACD has diverged and turned bullish, and the stochastic oscillator has followed suit, signaling a strong buy at current levels. The question is whether the market will follow through on those technical signals; it may take time for a sustained rally to gain traction. Even with a bullish outlook, the lack of revenue and profits remains a significant hurdle. The largest risk is execution and delay. The market is pricing in a robust growth trajectory — valuing the stock at more than 100x its initial-year earnings — and may be intolerant of setbacks. In that scenario, Oklo could experience notable volatility whether the rebound occurs soon or later. | 
